EUCTR2016-002529-12-SK
Active, not recruiting
Phase 1
A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
ConditionsHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Eye Diseases [C11]
DrugsExjade
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hereditary Hemochromatosis
- Sponsor
- ovartis Pharma AG
- Enrollment
- 150
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Male or female \= 18\-years\-old
- •\- Documented genotype testing confirming homozygous for the C282Y mutation (C282Y/C282Y)
- •\- Transferrin saturation \= 45% (at either screening visit)
- •\- Serum Ferritin \= 500 µg/L (at either screening visit)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 120
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 30
Exclusion Criteria
- •1\. Medical conditions that preclude inclusion:
- •\- Iron overload not due to HH
- •\- Condition which might significantly alter the absorption, distribution, metabolism or excretion of oral deferasirox
- •\- Systemic disease which prevents taking study treatment or any contraindication to phlebotomy
- •\- Inflammatory condition or immunological disease which may interfere with the SF interpretation, such as an active infection, collagen vascular disorders, irritable bowel syndrome, lupus, or immune thrombocytopenia
- •\- Significantly impaired gastrointestinal function or disease that may significantly alter the absorption of oral deferasirox, e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption
- •Hepatocellular carcinoma at any time is excluded.
- •2\. Prior iron chelation therapy, prohibited concomitant medications with deferasirox
- •syndrome, or small bowel resection.
- •\- Psychiatric or addictive disorder which prevent giving informed consent or undergoing any of the treatment options or unwilling or unable to comply with the protocol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2016-002529-12-DEovartis Pharma AG150
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHEUCTR2016-002529-12-BEovartis Pharma AG150
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with HHHereditary HemochromatosisMedDRA version: 20.0Level: LLTClassification code 10057874Term: Hereditary hemochromatosisSystem Organ Class: 100000012236Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2016-002529-12-ESovartis Farmacéutica, S.A.150
Active, not recruiting
Phase 1
A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanomaEUCTR2015-005097-37-FRniversity Hospital Essen176
Active, not recruiting
Phase 1
A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanomaEUCTR2015-005097-37-DEniversity Hospital Essen176